Outlook: Zeneca has been slow to change
Tuesday 02 December 1997
However, as Zeneca yesterday defended itself against accusations that it has failed to respond quickly enough to market changes and has let its drug pipeline run dry, it is Zeneca, not ICI, which looks unable to throw off the shackles of its old corporate identity. While ICI, under ex-Unilever man Charles Miller Smith, has been busy reinventing itself, swapping at record speed commodities business for high-margin speciality chemicals, Zeneca looks like it has only just caught the boat on many market developments - biotechnology alliances, genomics, for example - which have turned its more aggressive competitors Glaxo Wellcome and SmithKline Beecham into world forces in the drug industry.
Not surprisingly Zeneca has been a much better investment than ICI. Over the past four years, shares in Zeneca have outperformed the market by almost 70 per cent, compared to a dismal 21 per cent underperformance from ICI. However the chemicals and drugs sectors naturally attract different share price ratings. Moreover, much of Zeneca's share price growth has been driven by bid speculation.
There aren't many medium-sized drug companies left to buy and in an industry where global consolidation makes sense, Zeneca has been a natural bid target. Unfortunately, potential buyers look in short supply. Roche has splashed much of its cash on other acquisitions and Glaxo would have to think hard about another hostile bid, given the disruption that integrating Wellcome caused. Without a bidder, Zeneca looks exposed. Though it tried hard yesterday to point out how many new products it had coming on line, most of what it has to offer are new versions of existing drugs rather than a full pipeline of late-stage products ready to launch.
Zeneca's main problem is management in general and the congenial Sir David Barnes in particular. Those who know the company talk of an English gentleman's club atmosphere where never a harsh word is raised. In the absence of a bidder, things plainly need to change.
As Voltaire once said, “Ice cream is exquisite. What a pity it isn’t illegal”
- 1 Mother fed her daughter tapeworms to make her skinny for beauty pageant
- 2 Richard Dawkins on babies with Down Syndrome: 'Abort it and try again – it would be immoral to bring it into the world'
- 3 Crystal Palace next manager latest: Palace consider Ally McCoist - EXCLUSIVE
- 4 ALS ice bucket challenge co-founder Corey Griffin drowns, aged 27
- 5 Tim Sherwood column: 'It started as a three-horse race but turned into the Grand National'
'Alien thigh bone' on Mars: Excitement from alien hunters at 'evidence' of extraterrestrial life
West poised to join forces with Assad in face of Islamic State
Pamela Anderson rejects ice bucket challenge because of ALS experiments on animals: 'Mice had holes drilled into their skulls'
James Foley 'beheaded': Isis video shows militant with British accent 'execute US journalist' – as hunt begins for killer
ALS ice bucket challenge co-founder Corey Griffin drowns, aged 27
Richard Dawkins on babies with Down Syndrome: 'Abort it and try again – it would be immoral to bring it into the world'
Scottish independence: English people overwhelmingly want Scotland to stay in the UK
Isis threat: Cameron wants an alliance with Iran
Michael Brown shooting: Chaos erupts on the streets of Ferguson after autopsy shows teenager was shot six times – twice in the head
Bin bag full of cats' heads discovered near Manchester's Curry Mile
Disgusting, frustrating, but intriguing: how the country really feels about its politicians
iJobs Money & Business
£20000 - £27000 per annum: Harrington Starr: Service Desk Analyst- (Desktop Su...
£25000 - £35000 per annum: Harrington Starr: Service Desk Analyst - (Active Di...
£30000 - £50000 per annum: Harrington Starr: Junior Quant Analyst - C++, Boost...
£30000 - £50000 per annum: Harrington Starr: Junior Quant Analyst (Machine Lea...